The growth receptors and their role in wound healing

Current Opinion in Investigational Drugs

Volumn 11, Issue 11, 2010, Pages 1221-1228

  Rolfe, Kerstin J ^a   Grobbelaar, Adriaan O ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Chronic wound; growth factor; growth factor receptor; receptor tyrosine kinase; scarring; wound healing

Indexed keywords

AVOTERMIN; BECAPLERMIN; CAPTOPRIL; DISITERTIDE; EPIDERMAL GROWTH FACTOR; FG 3019; GROWTH FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INFLIXIMAB; JUVIDEX; JUVISTA; KERATINOCYTE GROWTH FACTOR; METELIMUMAB; PLACEBO; PROTEIN KINASE INHIBITOR; QUINAPRIL; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; RENOVO; SD 208; SEMAXANIB; SM 305; SOMATOMEDIN B RECEPTOR; SU 11657; SU 9518; TRANILAST; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN C; VATALANIB; ZK 22258;

ARTHRITIS; BURN; CROHN DISEASE; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; FIBROSIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; KERATOSIS; KIDNEY FIBROSIS; LIGAND BINDING; LIVER FIBROSIS; LUNG COMPLICATION; LUNG FIBROSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NONVIRAL GENE THERAPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SCAR FORMATION; SCLERODERMA; SKIN CANCER; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; ULCER; VIRAL GENE THERAPY; WOUND HEALING; WOUND HEALING IMPAIRMENT;

EID: 78650326730     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Singer AJ, Clark RA: Cutaneous wound healing. N Engl J Med (1999) 341(10):738-746.
2. Rajkumar T: Growth factors and growth factor receptors in cancer. Curr Sci (2001) 81(5):535-541.
3. Yu H, Mrowietz U, Seifert O: Down regulation of SMAD2, 4 and 6 mRNA and TGFβ receptor I mRNA in lesional and non-lesional psoriatic skin. Acta Derm Venereol (2009) 89(4): 351-356.
4. Schlessinger J: Cell signalling by receptor tyrosine kinases. Cell (2000) 103(2):211-225.
5. Posnett J, Franks PJ: The costs of skin breakdown and ulceration in the UK. In: Skin Breakdown: The silent epidemic. Pownall M (Ed), The Smith & Nephew Foundation, Hull, UK (2007)
6. Falanga V: Advanced treatments for non-healing chronic wounds. EWMA J (2004) 4(2):11-13.
7. Rowlatt U: Intrauterine wound healing in a 20 week human fetus. Virchows Arch A Pathol Anat Histol (1979) 381(3):353-361.
8. Woo SH, Seul JH: Optimizing the correction of severe postburn hand deformities by using aggressive contracture releases and fasciocutaneous free-tissue transfers. Plast Reconstr Surg (2001) 107(1):1-8.
9. Bayat A, McGrouther DA, Ferguson MW: Skin scarring. BMJ (2003) 326(7380):88-92.
10. Werner S, Krieg T, Smola H: Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol (2007) 127(5):998-1008.
11. Schultz GS, Wysocki A: Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen (2009) 17(2):153-162.
12. Werner S, Grose R: Regulation of wound healing by growth factors and cytokines. Physiol Rev (2003) 83(3):835-870. (Pubitemid 36828927)
13. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 344(14):1031-1037.
14. Cohen P: Protein kinases - The major drug targets of the twenty-first century? Nat Rev Drug Discov (2002) 1(4): 309-315.
15. Limvorasak S, Posadas EM: Kinase inhibitors in prostate cancer. Anticancer Agents Med Chem (2009) 9(10):1089-1104.
16. Rajkumar VS, Shiwen X, Bostrom M, Leoni P, Muddle J, Ivarsson M, Gerdin B, Denton CP, Bou-Gharios G, Black CM, Abraham DJ: Platelet-derived growth factor-β receptoractivation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol (2006) 169(6):2254-2265.
17. Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum (2007) 56(1):311-322.
18. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Gröne HJ, Lipson KE, Huber PE: Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med (2005) 201(6):925-935.
19. Kay J, High WA: Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum (2008) 58(8): 2543-2548.
20. Liu Y, Lui EL, Friedman SL, Li L, Ye T, Chen Y, Poon RT, Wo J, Kok TW, Fan ST: PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling. Lab Invest (2009) 89(2):209-221.
21. Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF, Huang XY, Wang T, Wang K, Wang X et al: VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int Immunopharmacol (2009) 9(1):70-79.
22. Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA et al: Progressive transforming growth factor β1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med (2005) 171(8):889-898.
23. Ishida W, Mori Y, Lakos G, Sun L, Shan F, Bowes S, Josiah S, Lee WC, Singh J, Ling LE, Varga J: Intracellular TGF-β receptor blockade abrogates SMAD-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol (2006) 126(8):1733-1744.
24. Prud'homme GJ: Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest (2007) 87 (11):1077-1091
25. Wang Q, Wang Y, Hyde DM, Gotwals PJ, Koteliansky VE, Ryan ST, Giri SN: Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters. Thorax (1999) 54(9):805-812.
26. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R: Dominant-negative soluble PDGF-β receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest (2004) 84(6):766-777.
27. Liu W, Chua C, Wu X, Wang D, Ying D, Cui L, Cao Y: Inhibiting scar formation in rat wounds by adenovirusmediated overexpression of truncated TGF-β receptor II. Plast Reconstr Surg (2005) 115(3):860-870.
28. Reid RR, Roy N, Mogford JE, Zimmerman H, Lee C, Mustoe TA: Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-β receptor II. J Plast Reconstr Aesthet Surg (2007) 60(1):64-72.
29. Pradhan L, Andersen ND, Nabzdyk C, et al: Woundhealing abnormalities in diabetes and new therapeutic interventions. US Endocrine Disease (2007) 1:68-72
30. Saaristo A, Tammela T, Farkkil? A, Kärkkäinen M, Suominen E, Yla-Herttuala S, Alitalo K: Vascular endothelial growth factor-C accelerates diabetic wound healing. Am J Pathol (2006) 169(3):1080-1087.
31. Kim BC, Kim HT, Park SH, Cha JS, Yufit T, Kim SJ, Falanga V:Fibroblasts from chronic wounds show altered TGF-β-signaling and decreased TGF-β type II receptor expression. J Cell Phsyiol (2003) 195(3):331-336.
32. Lee PY, Chesnoy S, Huang L: Electroporatic delivery of TGF-β1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol (2004) 123(4):791-78.
33. Kopp J, Wang GY, Kulmburg P, Schultze-Mosgau S, Huan JN, Ying K, Seyhan H, Jeschke MD, Kneser U, Bach AD, Ge SD et al: Accelerated wound healing by in vivo application of keratinocytes overexpressing KGF. Mol Ther (2004) 10(1):86-96.
34. Leask A, Abraham DJ: TGF-β signalling and the fibrotic response. FASEB J (2004) 18(7):816-827.
35. Vilchis-Landeros MM, Montiel JL, Mendoza V, Mendoza-Hernández G, López-Casillas F: Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-β neutralizing agent. Biochem J (2001) 355(Pt 1):215-222.
36. Juárez P, Vilchis-Landeros MM, Ponce-Coria J, Mendoza V, Hernández-Pando R, Bobadilla NA, López-Casillas F: Soluble betaglycan reduces renal damage progression in db/db mice. Am J Phsyiol Renal Physiol (2007) 292(1):F321-F329.
37. Santiago B, Gutierrez-Cañas I, Dotor J, Palao G, Lasarte JJ, Ruiz J, Prieto J, Borrás-Cuesta F, Pablos JL: Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol (2005) 125(3):450-455.
38. ISDIN SA: ISDIN and Digna Biotech commence phase II of the P-144 peptide for scleroderma. Press Release (2007): October 04.
39. Digna Biotech SL: Therapeutic pipeline: Development stage (2010). www.dignabiotech.com/images/Diapositiva1-018.JPG
40. McCormick LL, Zhang Y, Tootell E, Gilliam AC: Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human scleroderma. J Immunol (1999) 163(10):5693-5699.
41. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J et al: Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A muticenter, randomized, placebo-controlled phase I/II Trial of CAT-192. Arthritis Rheum (2007) 56(1):323-333.
42. Streit M, Beleznay Z, Braathen LR: Topical application of the tumour necrosis factor-α antibody infliximab improves healing of chronic wounds. Int Wound J (2006) 3(3):171-179.
43. Gary-Bobo M, Nirdé P, Jeanjean A, Morère A, Garcia M: Mannose 6-phosphate receptor targeting and its applications in human diseases. Curr Med Chem (2007) 14(28):2945-2953.
44. Juvidex Renovo, Manchester, UK (2009). www.renovo.com/ content.asp?c-id=37
45. Beer HD, Longaker MT, Werner S: Reduced expression of PDGF and PDGF receptors during impaired wound healing. J Invest Dermatol (1997) 109(2):132-138.
46. Fang RC, Galiano RD: A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics (2008) 2(1): 1-12.
47. Papanas N, Maltezos E: Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf (2010) 33(6):455-461.
48. Lee SW, Moon SY, Kim YH, Hong JP: The use of recombinant human epidermal growth factor to promote healing for chronic radiation ulcer. Int Wound J (2007) 4(3):216-220.
49. Kawai K, Suzuki S, Tabata Y, Ikada Y, Nishimura Y: Accelerated tissue regeneration through incorporation of basic fibroblast growth factor-impregnated gelatin microspheres into artificial dermis. Biomaterials (2000) 21(5):489-499.
50. Scevchenko RV, James SL, James SE: A review of tissueengineered skin bioconstructs available for skin reconstruction. J R Soc Interface (2010) 7(43):229-258.
51. Ferguson MW, O'Kane S: Scar-free healing: From embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci (2004) 359(1445):839-850
52. Laverty HG, Occleston NL, Johnson M, Little J, Jones R, Fairlamb D, Ferguson MW, O'Kane S. Effects of avotermin (transforming growth factor β3) in a clinically relevant pig model of long, full-thickness incisional wounds. J Cutan Med Surg (2010) 14(5):223-232.
53. Ferguson MW, Duncan J, Bond J, Bush J, Durani P, So K, Taylor L, Chantrey J, Mason T, James G, Laverty H et al: Prophylactic administration of avotermin for improvement of skin scarring: Three double-blind, placebo-controlled, phase I/II studies. Lancet (2009) 373(9671):1264-1274.
54. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K: Role and interaction of connective tissue growth factor with transforming growth factor-β in persistent fibrosis: A mouse fibrosis model. J Cell Physiol (1999) 181(1):153-159.
55. Ikawa Y, Ng PS, Endo K, Kondo M, Chujo S, Ishida W, Shirasaki F, Fujimoto M, Takehara K: Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-β-induced mouse fibrosis. J Cell Physiol (2008) 216(3):680-687.
56. Sisco M, Kryger ZB, O'Shaughnessy KD, Kim PS, Schultz GS, Ding XZ, Roy NK, Dean NM, Mustoe TA: Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo. Wound Repair Regen (2008) 16(5):661-673.
57. Chronic kidney disease: FibroGen, San Francisco, CA, USA (2010). www.fibrogen.com/ckd
58. Bascands JL, Schanstra JP: Bradykinin and renal fibrosis: Have we ACE'd it? J Am Soc Nephrol (2004) 15(9):2504-2506.
59. Huber LC, Distler JH, Moritz F, Hemmatazad H, Hauser T, Michel BA, Gay RE, Matucci-Cerinic M, Gay S, Distler O, Jüngel A: Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycininduced skin fibrosis. Arthritis Rheum (2007) 56(8):2755-2764.
60. Sharma A, Mehan MM, Sinha S, Cowden JW, Mohan RR: Trichostatin a inhibits corneal haze in vitro and in vivo. Invest Opthalmol Vis Sci (2009) 50(6):2695-2701.
61. Petrilli J, Wadsworth S, Cooper K, Rodgers KE, Siekierka J, diZerega GS: Tranilast: A pharmaceutical candidate for reduction of adhesions using a novel approach. Semin Reprod Med (2008) 26(4):341-348.
62. Qi W, Chen X, Twigg S, Polhill TS, Gilbert RE, Pollock CA: Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int (2006) 69(6):989-995.
63. Watts KL, Spiteri MA: Connective tissue growth factor expression and induction by transforming growth factor-β is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol (2004) 287(6):L1323-L1332.
64. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A: Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycininduced murine pulmonary fibrosis. Eur J Pharmacol (2008) 590(1-3):400-408.
65. Lagares D, Garca-Fernández RA, Jiménez CL, Magán-Marchal N, Busnadiego O, Lamas S, Rodrguez-Pascual F: Endothelin 1 contributes to the effect of transforming growth factor β1 on wound repair and skin fibrosis. Arthritis Rheum (2010) 62(3):878-889.
66. Liu H, Peng Y, Liu F, Li J, Chen X, Liu Y, Zhang H: A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-β1 synthesis and matrix production in human peritoneal mesothelial cells. Cell Biol Int (2007) 31(5):508-515.
67. Chau D, Mancoll JS, Lee S, Zhao J, Phillips LG, Gittes GK, Longaker MT: Tamoxifen downregulates TGF-β production in keloid fibroblasts. Ann Plast Surg (1998) 40(5):490-493.
68. Lopes LB, Furnish EJ, Komalavilas P, Flynn CR, Ashby P, Hansen A, Ly DP, Yang GP, Longaker MT, Panitch A, Brophy CM: Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-β1-induced CTGF expression in keloid fibroblasts. J Invest Dermatol (2009) 129(3):590-598.
69. Linge C, Richardson J, Vigor C, Clayton E, Hardas B, Rolfe K: Hypertrophic scar cells fail to undergo a form of apoptosis specific to contractile collagen-the role of tissue transglutaminase. J Invest Dermatol (2005) 125(1):72-82.
70. Henry SL, Concannon MJ, Kaplan PA, Diaz-Arias AA: The inhibitory effect of minocycline on hypertrophic scarring. Plast Reconstr Surg (2007) 120(1):80-88.
71. Wu Y, Chen L, Scott PG, Tredget EE: Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells (2007) 25(10):2648-2659.
72. Bajpai S, Shukla VK, Tripathi K, Srikrishna S, Singh RK: Targeting connexin 43 in diabetic wound healing: Future perspectives. J Postgrad Med (2009) 55(2):143-149